You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Trazodone hydrochloride
Trazodone hydrochloride is a 5-HT2A and α1 adrenoceptor antagonist. Enhances neuronal differentiation of mouse and human neural progenitor cells. Also inhibits PERK/eIF2α-P-mediated reduction in protein synthesis and restores memory deficits in a mouse dementia model. Antidepressant and neuroprotectant.
Compound Libraries for Trazodone hydrochloride
Trazodone hydrochloride is also offered as part of the Tocriscreen 2.0 Max, Tocriscreen FDA-Approved Drugs and Tocriscreen Stem Cell Library. Find out more about compound libraries available from Tocris.
Technical Data for Trazodone hydrochloride
|Store at RT
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Trazodone hydrochloride
|Max Conc. mg/mL
|Max Conc. mM
Preparing Stock Solutions for Trazodone hydrochloride
The following data is based on the product molecular weight 408.32. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass
Product Datasheets for Trazodone hydrochloride
References for Trazodone hydrochloride
References are publications that support the biological activity of the product.
Bortolotto et al (2017) Proneurogenic effects of traz. in murine and human neural progenitor cells. ACS Chem.Neurosci. 8 2027 PMID: 28636360
Halliday et al (2017) Repurposed drugs targeting eIF2α-P-mediated translational repression prevent neurodegeneration in mice. Brain 140 1768 PMID: 28430857
If you know of a relevant reference for Trazodone hydrochloride, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Trazodone hydrochloride, Trazodone hydrochloride supplier, 5-HT2A, alpha1, a1, α1, adrenoceptor, antagonist, antagonism, neuronal, differentiation, antidepressant, depression, neuroprotection, neuroprotectant, eIF2alpha, eIF2a, eIF2α, inhibitors, inhibits, Receptors, Adrenergic, Alpha-1, Neural, Stem, Cells, PERK, 6336, Tocris Bioscience
Citations for Trazodone hydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for Trazodone hydrochloride. Do you know of a great paper that uses Trazodone hydrochloride from Tocris? Please let us know.
Reviews for Trazodone hydrochloride
There are currently no reviews for this product. Be the first to review Trazodone hydrochloride and earn rewards!
Have you used Trazodone hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.